Next Phase Newsletter

A venture capital firm founded in 2016 that has offices in California and Washington State is actively investing in Seed to Series A rounds. In addition to providing equity capital, the firm will also assist companies with intellectual property. The firm is open to opportunities in North America (USA and Canada).

The firm is interested in early-stage medical technology, diagnostics, and digital health/wellness companies and is open to medical devices of all regulatory pathways including 510k and PMA. The firm strongly prefers products that have received FDA clearance but is open to working with pre-FDA products. The firm will generally not pursue opportunities in therapeutics.

The firm seeks to work with privately owned companies that are backed by an experienced management team. The firm likes to form syndicates and prefers co-investing in financing rounds, but the firm can lead rounds as well.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A pharma firm based in Japan, with a US licensing office in New Jersey, is seeking to form partnerships and in-licensing relationships regarding early stage assets in its key indication areas. These partnerships are highly flexible, and may involve the pharma firm contributing personnel, sharing studies and research tools, or providing research expense funding.

The firm is interested in early-stage, first-in-class, orally active small molecule NCEs. The firm seeks assets in the following key areas: metabolic disease, infectious disease, cardiovascular disease, and autoimmune disease. Additionally, the firm is interested in kidney disease, pain and osteoperosis. As well as drugs, the pharma firm is interested in drug targets in these disease areas. The firm is open to forming partnerships regarding very early stage assets, at or prior to the lead optimization phase.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A multi-stage venture capital firm in Europe invests in life science companies with a focus on niche indications with verified technology. The firm can allocate up to €10-15M per company and typically provides equity as well as debt financing. The firm generally acts as the lead or co-lead investor and is open to invest in syndicates. Currently, the firm seeks to invest in companies that are based in the European Union or US company that is open for an EU entity. The firm is actively seeking new investment opportunities.

The firm is currently seeking to invest in innovative biotech therapeutics and pharmaceuticals with clear biology and verified technology. The firm is also interested in exceptional medical devices with a therapeutic application that is close to market or has generated some sales. The firm is opportunistic across the therapeutic subsectors but prefers products that target niche indications. Currently, the firm is more interested in oncology and orphan indications.

The firm requests a board seat in each portfolio company. The firm seeks a strong and experienced management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A global insurance company based in Beijing, China has total assets under management of nearly US$800 billion. The firm’s investment arm has invested in several industries and is now looking for opportunities in healthcare. The firm is most interested in mature companies with stable cash flow, but it is also open to seed- and early-stage opportunities. The firm can lead or follow in a financing round, and the investment size can vary depending on the deal. The firm considers companies globally with a focus on North America.

The firm considers opportunistically across various sectors within healthcare, including therapeutics, medical devices, diagnostics, and healthcare IT, with an increased interest in senior care, wellness, wearable devices, and big data analytics. The firm prefers revenue-generating, mature businesses, while early-stage companies with proof-of-concept would also be considered.

The firm is looking for experienced management teams with sector expertise.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A private equity firm based in San Francisco, CA has partnered with an established healthcare investor to form a new fund of almost $200 million, focused on the healthcare sector. The firm typically makes equity investments between $5-30 M (USD), although the firm has made smaller and larger deals on a case-by-case basis. In addition, the firm also participates in buyouts and restructuring deals. The firm seeks to invest about $45 M per year, and looks for companies globally with a focus in North America.

The firm looks at all sectors within the life science space. The firm has invested the most in medical devices, diagnostics, healthcare IT/services, and biopharma/therapeutics, in descending order. With all sectors, the firm’s focus lies in products already on the market although they will look at clinical products that have novel technologies and clear regulatory pathways. The firm will participate in financing rounds no earlier than Series B or C rounds. In therapeutics, the firm will consider assets in Phase II clinical trials and beyond. In medical devices, the firm will look at 510k and PMA devices that are in the cusp of receiving FDA clearance.

The firm seeks to work with companies with strong, dedicated management teams with a track record of success. While positive revenue is not an absolute requirement, the firm’s portfolio companies generate an average of $10 – 20 M revenue. The firm does not generally require a board seat; currently, the firm has a board seat in approximately 20% of portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm based in Fort Lauderdale, FL has launched its first fund, aimed at a $50M close. The firm seeks to invest in early-stage technology companies, including those with digital health/healthcare IT products. The firm will generally make equity investments in the $1-2.5 M range but can also deploy smaller, angel investments and provide follow-on investments as the company grows. The firm is looking to secure 3-4 deals per year. The firm will consider all companies based in the US with a focus in the Southeast region.

In the life sciences field, the firm has a strong focus in healthcare IT and is not open to opportunities in therapeutics, medtech, or diagnostics. Digital health products are expected to demonstrate strong market traction with ongoing post-pilot sales.

The firm will support privately owned companies with an experienced management team with a track record of success and the ability to properly execute strong business plans. These companies should be generating minimum $500K revenue, but ideally closer to $1M. The firm prefers to lead financing rounds and will generally seek board representation, as the firm seeks to be an active part of its portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A pharmaceutical enterprise headquartered in Beijing, China has set up a biotech subsidiary in Massachusetts and is actively seeking cutting-edge life science technologies around the world. The firm makes equity investments of US$2-10 million in Seed to Series B stage companies, while later stages up to pre-IPO may also be considered. For overseas deals, the firm prefers to co-invest with top-tier lead investors. The firm is looking for opportunities across the globe.

The firm is looking for technologies across biopharmaceuticals, medical devices, and healthcare services that are a strategic fit with its portfolio. The firm is most interested in innovative platform technology in small molecule or biologic therapeutics targeting large disease markets in China. The firm considers early-stage companies from seed to Series B stage.

The firm seeks experienced management teams backed by strong, reputable VC firms. The firm typically requests board representation post-investment. The firm prefers to retain China rights, but this is not a requirement for investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com